Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy
Chenlu Yang, Yuanqi Mi, Yuhong Zeng, Feng Cheng, Huatang Zeng, Mengge Zhou · 2026
Read Cost-effectiveness analysis of efavirenz versus ainuovirine in people living with HIV initiating first-line combination antiretroviral therapy by Chenlu Yang, Yuanqi Mi, Yuhong Zeng, Feng Cheng, Huatang Zeng, Mengge Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13599928.txt.
Description
Chenlu Yang, Yuanqi Mi, Yuhong Zeng, Feng Cheng, Huatang Zeng, and Mengge Zhou wrote this 2026 study on the value for money of a new HIV drug in China. The drug, ainuovirine, matches the standard drug efavirenz in effect but causes fewer side effects. Whether swapping to it pays off inside China's free treatment program was unknown.
The team built decision and Markov models that follow patients for fifteen years, counting costs, healthy years gained, and side effects. Inputs came from a Chinese cohort and field surveys. The new drug cut the total of side effects a great deal and added a small gain in healthy years, at a modestly higher cost. The pattern held for both new and seasoned patients. Checks that vary the inputs tested how firm the verdict is.
Catalog record
| CREATOR | Chenlu Yang, Yuanqi Mi, Yuhong Zeng, Feng Cheng, Huatang Zeng, Mengge Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |